from the world's big
Big Pharma, Meet the Future
Fred Hassan is chairman and chief executive officer of Schering-Plough Corporation. Prior to his arrival at Schering-Plough in April 2003, Hassan was chairman and chief executive officer of Pharmacia Corporation. He received a bachelor's degree in chemical engineering from the Imperial College of Science and Technology at the University of London and an M.B.A. from Harvard Business School.
Question: What do you think of startups that give people access to their genetic information?
Fred Hassan: I think knowing one's personal information gives one tremendous power, because now one can say, look, I might have a higher risk of breast cancer or a higher risk of Alzheimer's, and what can I start doing now to do better regarding exercise, diet, even some interventions now, so that I can delay the onset of a possible problem by several years or even decades? That's an opportunity for the industry. The fact that people can learn more about themselves, and number two, take on a lifetime of disease management for themselves -- this is a very, very good development because it makes people more responsible for their own health care. And if our industry can develop the tools and can relate to this new development with new innovations, new drugs, that are very specific to individual people or to subpopulations of people, then it's a chance to reduce the waste that exists in our system in failed clinical trials, and also to reduce the waste in terms of medicines that might be taken by people that may not work or that might cause side effects. So it's a tremendous, disruptive opportunity for the individual as well as the industry.
I think the industry is very good at what it does, and there are always groups inside the industry that are very forward-looking and that are very anxious to be moving in this direction. You always have smaller companies coming up, and maybe with more flexibility and with more creativity, that are more in tune with the more recent trends. In terms of personalized medicines, the one big hope that we have is that communities of patients will start to group together once they know more about themselves, and as a result of grouping together they will then create the pressure from the bottom toward the regulatory authorities to also improve the flow of medicines.
A good example is that when the community of patients with HIV started to come together in the '80s and create this bottom-up pressure, that's when the regulatory pathway started to open up. And as a result we have now seen that in less than 25 years we've not only been able to describe a new disease that's emerged, but also describe the virus and then start to come up with drugs that have stabilized the disease. What used to be a death sentence has now become a chronically managed disease. I believe a lot of the disruptive change can occur from the patients up, as opposed to only coming from the manufacturers.
Question: How with big pharma companies fit into this genetic innovation?
Fred Hassan: I think we will see both acquisitions, but more importantly partnerships. Some companies might make acquisitions just to bring a change in their internal DNA. You literally buy a smaller company and use that opportunity to change the internal DNA. In many other cases, companies will seek to partner with smaller companies to acquire their expertise, to also improve their own internal DNA and to be a part of the opportunity here that's definitely going to open up. It's already happened in breast cancer to some extent, because now we know that about 25 percent of breast cancers are HER2 positive, and they need to be treated separately from the other 75 percent, and that there is a drug called Herceptin that works very well in these 25 percent of breast cancers. Similarly, as patients start to learn more about other kinds of diseases, such as Alzheimer's, and know that there might be specific approaches to their subset of Alzheimer's disease, you will see a tremendous demand coming from that area and big companies reaching out to smaller companies with expertise to help them meet that demand.
Recorded on November 6, 2009
It's a tremendous, disruptive opportunity for the individual as well as the industry.
Educators and administrators must build new supports for faculty and student success in a world where the classroom might become virtual in the blink of an eye.
- If you or someone you know is attending school remotely, you are more than likely learning through emergency remote instruction, which is not the same as online learning, write Rich DeMillo and Steve Harmon.
- Education institutions must properly define and understand the difference between a course that is designed from inception to be taught in an online format and a course that has been rapidly converted to be offered to remote students.
- In a future involving more online instruction than any of us ever imagined, it will be crucial to meticulously design factors like learner navigation, interactive recordings, feedback loops, exams and office hours in order to maximize learning potential within the virtual environment.
Placing science and religion at opposite ends of the belief spectrum is to ignore their unique purposes.
- Science and religion (fact versus faith) are often seen as two incongruous groups. When you consider the purpose of each and the questions that they seek to answer, the comparison becomes less black and white.
- This video features religious scholars, a primatologist, a neuroendocrinologist, a comedian, and other brilliant minds considering, among other things, the evolutionary function that religion serves, the power of symbols, and the human need to learn, explore, and know the world around us so that it becomes a less scary place.
- "I think most people are actually kind of comfortable with the idea that science is a reliable way to learn about nature, but it's not the whole story and there's a place also for religion, for faith, for theology, for philosophy," says Francis Collins, American geneticist and director of the National Institutes of Health (NIH). "But that harmony perspective doesn't get as much attention. Nobody is as interested in harmony as they are in conflict."
Studying voice recordings of infected but asymptomatic people reveals potential indicators of Covid-19.
A leading British space scientist thinks there is life under the ice sheets of Europa.
- A British scientist named Professor Monica Grady recently came out in support of extraterrestrial life on Europa.
- Europa, the sixth largest moon in the solar system, may have favorable conditions for life under its miles of ice.
- The moon is one of Jupiter's 79.
Neil deGrasse Tyson wants to go ice fishing on Europa<div class="rm-shortcode" data-media_id="GLGsRX7e" data-player_id="FvQKszTI" data-rm-shortcode-id="f4790eb8f0515e036b24c4195299df28"> <div id="botr_GLGsRX7e_FvQKszTI_div" class="jwplayer-media" data-jwplayer-video-src="https://content.jwplatform.com/players/GLGsRX7e-FvQKszTI.js"> <img src="https://cdn.jwplayer.com/thumbs/GLGsRX7e-1920.jpg" class="jwplayer-media-preview" /> </div> <script src="https://content.jwplatform.com/players/GLGsRX7e-FvQKszTI.js"></script> </div>
Water Vapor Above Europa’s Surface Deteced for First Time<span style="display:block;position:relative;padding-top:56.25%;" class="rm-shortcode" data-rm-shortcode-id="9c4abc8473e1b89170cc8941beeb1f2d"><iframe type="lazy-iframe" data-runner-src="https://www.youtube.com/embed/WQ-E1lnSOzc?rel=0" width="100%" height="auto" frameborder="0" scrolling="no" style="position:absolute;top:0;left:0;width:100%;height:100%;"></iframe></span>
A study finds people are more influenced by what the other party says than their own. What gives?
- A new study has found evidence suggesting that conservative climate skepticism is driven by reactions to liberal support for science.
- This was determined both by comparing polling data to records of cues given by leaders, and through a survey.
- The findings could lead to new methods of influencing public opinion.